Publicaciones (653) Publicaciones en las que ha participado algún/a investigador/a

2018

  1. 11 C-PE2I and 18 F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study

    Movement Disorders, Vol. 33, Núm. 1, pp. 117-127

  2. 68Ga-PSMA PET/CT in prostate cancer

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 37, Núm. 2, pp. 130-138

  3. Alterations in Gene and Protein Expression of Cannabinoid CB 2 and GPR55 Receptors in the Dorsolateral Prefrontal Cortex of Suicide Victims

    Neurotherapeutics, Vol. 15, Núm. 3, pp. 796-806

  4. Assessment of metabolic patterns and new antitumoral treatment in osteosarcoma xenograft models by [ 18 F]FDG and sodium [ 18 F]fluoride PET

    BMC Cancer, Vol. 18, Núm. 1

  5. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus

    European Journal of Neurology, Vol. 25, Núm. 10, pp. 1201-1217

  6. The CO 2 -dependence of Brucella ovis and Brucella abortus biovars is caused by defective carbonic anhydrases

    Veterinary Research, Vol. 49, Núm. 1

  7. A 60-Year-Old Male Smoker With Chronic Obstructive Pulmonary Disease and Hypereosinophilia

    Archivos de Bronconeumologia, Vol. 54, Núm. 7, pp. 394-395

  8. A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers

    Brain, Vol. 141, Núm. 10, pp. 2895-2907

  9. A European, Observational Study of Endocrine Therapy Administration in Patients With an Initial Diagnosis of Hormone Receptor-Positive Advanced Breast Cancer

    Clinical Breast Cancer, Vol. 18, Núm. 4, pp. e613-e619

  10. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization

    Cell, Vol. 175, Núm. 2, pp. 313-326

  11. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

    EMBO Molecular Medicine, Vol. 10, Núm. 12

  12. A Technology-Enabled Solution to Manage Referrals to Hospice and Palliative Care Beds: The Ottawa SMART System as a Case Study

    Healthcare quarterly (Toronto, Ont.), Vol. 20, Núm. 4, pp. 63-67

  13. A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers

    Nature Communications, Vol. 9, Núm. 1

  14. A multicentre, randomized controlled trial of telehealth for the management of COPD

    Respiratory Medicine, Vol. 144, pp. 74-81

  15. A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients

    Journal of Pathology, Vol. 245, Núm. 4, pp. 421-432

  16. A phase ii multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy

    Haematologica, Vol. 103, Núm. 8, pp. 1351-1358

  17. A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma

    Oncogene, Vol. 37, Núm. 27, pp. 3740-3752

  18. A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis

    Journal for ImmunoTherapy of Cancer, Vol. 6, Núm. 1

  19. A systematic review of current immunological tests for the diagnosis of cattle brucellosis

    Preventive Veterinary Medicine, Vol. 151, pp. 57-72

  20. A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity

    Nature Communications, Vol. 9, Núm. 1